Skip to main content

Table 2 Literature review of hypofractionated radiotherapy outcomes for the treatment of prostate cancer in the postoperative setting

From: Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial

Study (ref.) Median follow-up, months bPFS, % Toxicity scoring system Acute toxicity, % Late toxicity, %
GU GI GU GI
Tandberg [30] 38.6 78.4a (4 years) CTCAE v4.0b/RTOGc ≥ G2: 22; G3: 1d G2: 5; ≥ G3: 0 G2: 39; ≥ G3: 11 G2:10; G3: 1d
Kruser [33] 32.4 67 (4 years) RTOG G2: 6.4; G3: 1d G2: 14; ≥ G3: 0 G2: 15; ≥ G3: 0 G2: 4; ≥ G3: 0
Lewis [31] 48 75 (4 years) CTCAE v4.0b/RTOGc G2: 4; ≥ G3: 0 G2: 4; ≥ G3: 0 G2: 39; G3: 28 ≥ G3: 2d
Cuccia [32] 30 73 (3 years) CTCAE v4.0 G2: 4; ≥ G3: 0 G2: 18; ≥ G3: 0 G2: 2.6; G3: 2.6 G2: 6.6; ≥ G3: 0
Barra [34] 15.5 Not reported CTCAE v4.0b/RTOGc ≥ G2: 0 ≥ G2: 0 G2: 3.3; G3: 3.3 ≥ G2: 0
Alongi [35] 22.8 Not reported RTOG G2: 10; ≥ G3: 0 G2: 20; ≥ G3: 0 G2: 8; G3: 3 ≥ G2: 0
Saldi [27] 27 Not reported CTCAE v4.0 G2: 8.9; ≥ G3: 0 G2: 9.8; ≥ G3: 0 Not reported Not reported
Katayama [26] Not reported Not reported CTCAE v4.0 ≥ G2: 0 G2: 17.9; ≥ G3: 0 Not reported Not reported
Gladwish [29] 24 Not reported CTCAE v3.0b/RTOGc G2: 3; G3: 3 ≥ G2: 0 ≥ G2: 1d ≥ G2: 2d
Macchia [28] 30 86.5 (5 years) RTOG G2: 17.7; G4: 1d G2: 24.2; ≥ G3: 0 ≥ G2: 7.3 ≥ G2: 1.1
  1. bPFS biochemical progression-free survival, GU Genitourinary, GI gastrointestinal
  2. aPatients with a 12-month minimum follow-up were analyzed for bPFS
  3. bAcute
  4. cLate
  5. dNumber of patients